arrow
M

Maria Cristina Albertini

University of Urbino Carlo Bo
H指数:36
被引数:4,860

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bronchopulmonary Dysplasia Starts in Utero: MicroRNA Dysregulation Across the Fetal–Neonatal Continuum in the Bronchopulmonary Dysplasia Development

支气管肺发育不良始于宫内:支气管肺发育不良发展过程中胎儿-新生儿连续体中的微小RNA失调

2026-11-020
OAAI
Pulp Callus Extract From Malus domestica var. Mela Rosa Marchigiana Preserves Intestinal Barrier Integrity and Confers Neuroprotection in a Gut–Brain Axis Co-Culture Model

苹果品种马拉罗萨马尔凯尼亚的愈伤组织提取物可维持肠道屏障完整性,并在肠道-大脑轴共培养模型中提供神经保护作用

2026-09-290
OAAI
Attenuating Monocytic Inflammaging via the miR-146a/TLR4 Axis: Characterization and Bioactivity of a Triterpenoid-Rich Callus Phytocomplex

通过miR-146a/TLR4轴减弱单核细胞炎症衰老:富含三萜类物质的愈伤组织植物复合物的表征与生物活性

2026-09-070
OAAI
Challenges in assessing bone health in early infancy: a narrative review of existing technologies

早期婴儿骨骼健康评估的挑战:现有技术的叙事性综述

2025-10-210
OAAI
Antioxidant and Analgesic Effect of Melatonin Involving Sirtuin 1: A Randomised Pilot Clinical Study

褪黑素通过Sirtuin 1发挥抗氧化和镇痛作用的随机试点临床研究

2025-05-190
OA
Characteristics, treatment options, and predictors of clinical failure among Pseudomonas aeruginosa infection with microbiologically confirmed intermediate or resistant carbapenem susceptibility profile: a multicenter clinical experience on behalf of CASPER (CArbapenem-reSistant Pseudomonas aERuginosa during and after the COVID-19 pandemic) study group

铜绿假单胞菌(Pseudomonas aeruginosa)感染且微生物学证实其对碳青霉烯类药物表现为中介或耐药的敏感性特征、治疗选择及临床失败预测因素:代CASPER(碳青霉烯耐药铜绿假单胞菌在COVID-19大流行期间及之后的CARBapenem-reSistant Pseudomonas aERuginosa)研究组的多中心临床经验

2025-04-240
OA
In vitro anti-inflammatory activity of Malus x domestica var. Mela Rosa Marchigiana pulp callus extract contrasting high glucose conditions
2024-10-010
OAAI
Long-lasting bioactive compounds production from Malus x domestica Borkh var. Mela Rosa Marchigiana pulp callus culture with antioxidant activity: In vitro, ex vivo and in vivo validation
2024-03-011
OAAI
Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework
2022-07-3119
OAAI